BCa-PROteom +KardiOM +RenOM Three-in-One Test
Description: BCa-PROteom + KardiOM + RenOM
Please also read our Product data sheet and the recommendations/instructions at the end of this page.
BCa-PROteom + KardiOM + RenOM Three-in-One Test consists of the following three individual tests
The DiaPat BCa-PROteom-Test is based on the non-invasive urine proteome analysis where proteins in the urine are measured by the very sensitive CE-MS technology. By CE-MS, a unique urine profile is created and screened in a fast and highly accurate diagnostic procedure for the abundance of 116 cancer-related molecular markers that together indicate whether a patient with suspicious symptoms has bladder cancer or not. These early and accurate test results give patients the particular advantage to check their health status in regular intervals and without the need for painful and invasive cytoscopy. Early diagnosis of bladder cancer, particularly when the tumor is limited to the inner surface of the bladder wall, increases treatment options and the chance of survival.
The DiaPat® KardiOM is a test in urine that predicts the risk of heart failure caused by calcified arteries (arteriosclerosis). Before the first clinical symptoms occur, the DiaPat® KardiOM test very reliably detects even the smallest, not yet visible plaque deposits by analyzing 238 arteriosclerosis-specific proteins. The test is currently the only diagnostic tool available to detect plaques at this early stage. Based on these test characteristics, the DiaPat® KardiOM test ensures timely diagnosis and significantly improves the success of therapy so that heart attack and ischemic stroke can be prevented. The DiaPat® KardiOM test is a clinically validated valuable method for early detection and subsequent therapy guidance.
By the analysis of kidney disease-specific proteins in the urine, the DiaPat® RenOM test enables early detection and differentiation of chronic kidney diseases. The urine test has been validated in a variety of clinical studies. It reliably detects pathologic changes in the kidneys before persistent organ damage occur. Timely therapy after a positive DiaPat® RenOM test result can delay or prevent the complete loss of kidney function and the necessity for kidney replacement therapy (dialysis or kidney transplantation) that is then required. The DiaPat® RenOM test differentiates between the following chronic kidney diseases:
- Diabetic nephropathy
- Minimal Change Disease (MCD)
- Membranous glomerulonephritis (MGN)
- Focal segmental glomerulosclerosis (FSGS)
- IgA-nephropathy (IgAN)
- Lupus nephritis
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
Instructions for use
For the DiaPat® test, the midstream of second morning urine is collected in a urine cup. The urine is then transferred to the enclosed urine monovette (sample syringe) *. The urine monovette is placed in protective packaging* for transport. Transport to the laboratory will be carried out per overnight express (see also instructions for use).
*These materials will be provided as part of the DiaPat® sample collection kit
The DiaPat® test includes the following services:
The DiaPat® package includes the sample set for collecting the urine sample and all the necessary documents. The shipment will be operated by a courier by home pickup or via the doctor's office.
The analysis will be conducted in our central laboratory using the CE-MS technology.
Medical history questionnaire form
A detailed medical history questionnaire is part of the sampling kit. Please fill it out carefully and completely. The information is the basis for a reliable evaluation of the DiaPat® test result.
Send the result letter to your family doctor
The result of the protein analysis, which we send to your doctor, is explained in detail and gives recommendations for further diagnostic steps.